RCUSArcus Biosciences, Inc.
Is the business good?
Margins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is RCUS?
Arcus Biosciences, Inc. spent more than it took in: an operating loss of $486M on $117M of revenue, 12 months to Q2 2026.
Operating loss · on $117M of revenue · 12 months to Q2 2026
- Share count, year on year
- +18%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −159% |
| FY2021 | 14% |
| FY2022 | −250% |
| FY2023 | −291% |
| FY2024 | −128% |
| FY2025 | −156% |
Details›
- Operating margin12 months to Q2 2026
- −415%
- Net margin12 months to Q2 2026
- −393%
- Free cash flow margin
- −406%
- R&D as % of revenue
- 425%
- Revenue, trailing twelve months
- $117M
- Free cash flow, trailing twelve months
- −$475M
- Net income, trailing twelve months
- −$460M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from RCUS and who it buys from, as the companies report it.
- GILDGilead Sciences97%
Share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; RCUS’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.